Suratadenoturev
- Generic Name
- Suratadenoturev
- Drug Type
- Biotech
- CAS Number
- 1268642-13-2
- Unique Ingredient Identifier
- FV0JG1SX76
- Background
Suratadenoturev is a gene-modified oncolytic adenovirus expressing the telomerase reverse transcriptase gene.
Esophageal Cancer Treatment Landscape Evolves with Novel Therapies and Approvals
• The esophageal cancer market is expected to grow significantly, driven by increasing prevalence and the introduction of novel therapies.
• In 2023, approximately 77,000 new cases of esophageal cancer were reported across seven major markets, with Japan having the highest number.
• Recent FDA approval of TEVIMBRA (tislelizumab) as a monotherapy marks a significant advancement in treating unresectable or metastatic ESCC.
• Emerging therapies like zanidatamab and bemarituzumab are expected to revolutionize the esophageal cancer market dynamics during the forecast period.
Advances in the Clinical Development of Oncolytic Viruses
This article reviews the progress in clinical trials of oncolytic viruses (OVs) for cancer treatment, highlighting their safety, effectiveness, and the challenges faced in their development. OVs selectively infect and kill cancer cells without harming normal cells, showing promise in treating various tumors with mild adverse events.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath